Biopharma Company and Doctors Sue Trump Administration Over Marijuana Rescheduling
A biopharmaceutical company working on cannabinoid-derived drugs has joined doctors and anti-cannabis reform groups in suing the Trump administration over its proposal to reschedule marijuana as a Schedule III substance. The lawsuit challenges the administration's decision, which could impact drug development and regulatory frameworks.
Topics: biopharmaceutical industry legal challenge marijuana rescheduling